About
Circuit-Bio is a synthetic biology company developing a unique platform of logical gene circuits for cancer immunotherapy. The company's platform focuses on generating gene circuits able to locally and accurately produce a combination of multiple immune-stimulating proteins (immunomodulators) exclusively expressed in targeted tumor cells. The circuit selectively converts cancer cells into 'Trojan horses' utilized as an anti-tumor resource that triggers a robust, long-term, anti-tumor immune response. The immunomodulators' output is tightly controlled by two de novo synthetic cancer-specific promoters (SPECS) and specifically enhances a Boolean AND gate, which enables multi-output gene expression only when both synthetic promoters are activated simultaneously. This emerging bio-convergence approach differentiates itself from other immunotherapy treatments by a unique tunable mode of action and therefore can overcome some of the major obstacles arising from the treatment of immunotherapeutic drugs. The circuit modularity can be reflected by the ability to control and adapt each of the circuit components to the treated indication, such as selecting the most effective tumor-specific immunomodulator combination output.